Stocks of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) traded higher last session on Wall Street, down -15.83% to $21.53.
According to the data, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 16 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $42.00 and a low of $13.00, we find $33.00. Given the previous closing price of $25.58, this indicates a potential upside of 29.01 percent. ACAD stock price is now -21.54% away from the 50-day moving average and -3.44% away from the 200-day moving average. The market capitalization of the company currently stands at $3.53B.
A total of 7 analysts have issued a hold rating and 8 have given it a buy rating. Brokers who have rated the stock have averaged $31.93 as their price target over the next twelve months.
With the price target maintained at $22, Guggenheim recently Upgraded its rating from Neutral to Buy for Acadia Pharmaceuticals Inc (NASDAQ: ACAD).
In other news, Kihara James, Principal Accounting Officer sold 2,000 shares of the company’s stock on Sep 15. The stock was sold for $51,760 at an average price of $25.88. Upon completion of the transaction, the Principal Accounting Officer now directly owns 10,778 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 21, EVP, Chief Financial Officer Schneyer Mark C. sold 10,000 shares of the business’s stock. A total of $289,970 was realized by selling the stock at an average price of $29.00. This leaves the insider owning 15,682 shares of the company worth $0.34 million. Insiders disposed of 278,398 shares of company stock worth roughly $5.99 million over the past 1 year. A total of 0.77% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACAD stock. A new stake in Acadia Pharmaceuticals Inc shares was purchased by OPALEYE MANAGEMENT INC. during the first quarter worth $4,672,000. PENN CAPITAL MANAGEMENT COMPANY, LLC invested $4,026,000 in shares of ACAD during the first quarter. In the first quarter, HILLSDALE INVESTMENT MANAGEMENT INC. acquired a new stake in Acadia Pharmaceuticals Inc valued at approximately $2,393,000. PARKMAN HEALTHCARE PARTNERS LLC acquired a new stake in ACAD for approximately $2,153,000. EDGESTREAM PARTNERS, L.P. purchased a new stake in ACAD valued at around $1,812,000 in the second quarter. In total, there are 334 active investors with 97.78% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $25.00 for Acadia Pharmaceuticals Inc (NASDAQ: ACAD). During the past 12 months, Acadia Pharmaceuticals Inc has had a low of $13.73 and a high of $33.99. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 2.62, and a quick ratio of 2.57. The fifty day moving average price for ACAD is $27.44 and a two-hundred day moving average price translates $22.30 for the stock.
The latest earnings results from Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.01, beating analysts’ expectations of -$0.08 by 0.09. This compares to -$0.21 EPS in the same period last year. The net profit margin was -20.12% and return on equity was -26.68% for ACAD. The company reported revenue of $165.24 million for the quarter, compared to $134.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.79 percent. For the current quarter, analysts expect ACAD to generate $187.79M in revenue.
Acadia Pharmaceuticals Inc(ACAD) Company Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
